CLOSE
MENU
Chordia Therapeutics Inc.
Investor Relations
Investor Relations
サブ-ナビゲーション
Company
Science/Pipleline
News
現在位置:
Investor Relations
Management Policies
Financial Information
IR Library
Stock Information
IR Calender
IR News
IR FAQ
Disclaimer
Career
Contact
Privacy Policy
Term of use
Sitemap
Investor Relations
Top Message
Financial Highlights
IR News
Jan 14, 2025
Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP]
(432KB)
Jan 10, 2025
Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA
(272KB)
Dec 12, 2024
By FISCO Corporation Notice of Distribution of Our Corporate Research Report
(267KB)
Nov 29, 2024
Corporate Governance Report
(659KB)
Nov 20, 2024
Announcement of International Nonproprietary Name (INN) for CTX-712
(277KB)
IR News
IR Calenar
Mid-Jul-24
Announcement of 3Q Financial results of FY2025
Latest financial statements
複製用パーツ:20XX年X月期 第X四半期 (英文:FY20XX QX)
リンクタイトル
(0KB)
FY2024
Fiscal year ended August 2024 Financial Results (Transcript)
(2,714KB)
FY2025 (1Q)
Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP]
(432KB)
FY2024
Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2024 [Japanese GAAP]
(538KB)
Fiscal year ended August 2024 Financial Results Presentation
(1,465KB)
FY2024 (3Q)
Non-consolidated Financial Results for the Nine Months Ended May 31, 2024 [Japanese GAAP]
(348KB)
Management Policies
Top Message
Discloser Policy
Corporate Governance
Financial Information
Financial Highlights
Financial Indicators
Cash Flow
IR Library
Financial Results
Stock Information
General Meeting of Shareholders
Stock Price
IR Calender
IR FAQ
Disclaimer
ページの先頭へ
ページの先頭へ
menu
gnavi-box
複製用パーツ:20XX年X月期 第X四半期 (英文:FY20XX QX)
FY2024